胸膜炎疼痛治療市場規模、佔有率和成長分析：按治療類型、給藥途徑、最終用戶、分銷管道、患者群體和地區分類 - 行業預測，2026-2033 年

2024 年全球胸膜炎疼痛治療市場價值為 1.863 億美元，預計到 2033 年將從 2025 年的 1.9729 億美元成長到 3.1209 億美元，預測期（2026-2033 年）的複合年成長率為 5.9%。

全球胸膜炎疼痛治療市場的發展動力源自於對有效緩解克沙奇病毒B感染所致疼痛療法的需求。症狀的快速出現和頻繁的誤診導致成人患者生產力顯著下降，促使臨床實踐中對該疾病的認知和處方量不斷增加。這推動了創新鎮痛藥和抗病毒療法的問世。此外，門診病人藥物配送網路的擴展提高了藥物的可及性，遠端醫療的整合使患者能夠快速獲得抗病毒藥物和鎮痛藥的聯合治療，從而最大限度地減少就醫次數。人工智慧驅動的藥物發現也在革新該領域，它加速了抗病毒候選藥物的識別並降低了研發成本，使各種規模的公司都能專注於特定療法。這種充滿活力的市場環境正在推動進一步的投資和成長。

全球胸膜疼痛治療市場促進因素

全球胸膜炎疼痛盛行率的上升提高了醫療專業人員的認知，並促使他們對出現胸痛和腹痛等症狀的患者進行更全面的評估。這種臨床意識的提高導致現有療法的處方率上升，並激發了人們對創新療法的興趣。隨著醫療專業人員診斷出更多確診病例，標準化管理方案的採用也不斷推進，適合藥物治療的患者群體也不斷擴大。這些趨勢推動了全球胸膜炎疼痛治療市場的持續成長和發展，反映了全球範圍內治療選擇機會的不斷增加。

全球胸膜疼痛治療市場的阻礙因素

由於缺乏針對胸膜炎疼痛的詳細治療方案，臨床醫師在選擇最佳治療策略和適當劑量方面存在不確定性，往往依賴個人經驗而非實證指引。這種不確定性導致已獲已通過核准藥物的處方延遲，並促使醫生更多地依賴支持性治療，最終可能降低對專科治療的需求。此外，醫療系統可能不願意投資於缺乏強力指南支持的療法。這限制了市場滲透率，阻礙了整體市場成長，即便在疾病盛行率不斷上升且保險報銷選擇有限的情況下也是如此。

全球胸膜炎疼痛治療市場趨勢

全球胸膜炎疼痛治療市場正經歷著向個人化醫療的重大轉變，這主要得益於針對特定病毒株和個別免疫反應的新型免疫療法的出現。基因測序和生物標記識別技術的進步，為疫苗樣療法和針對每位患者獨特特徵量身定做的單株抗體等創新方法鋪平了道路。這一趨勢也吸引了製藥公司加強投資，他們渴望改善症狀管理、降低復發率，並將患者特異性數據整合到治療方案中。學術界、臨床實踐和產業界之間的合作網路對於制定符合監管標準的有效方案以及進一步推動市場成長至關重要。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球胸膜炎疼痛治療市場規模：依治療類型分類

• 止痛藥
• 非類固醇消炎劑（NSAIDs）
• 抗病毒治療
• 支持性護理

全球胸膜炎疼痛治療市場規模：依給藥途徑分類

• 口服
• 注射
• 外用

全球胸膜炎疼痛治療市場規模：依最終用戶分類

• 醫院
• 診所
• 居家照護

全球胸膜炎疼痛治療市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球胸膜炎疼痛治療市場規模：依患者族群分類

• 兒童
• 成人

全球胸膜炎疼痛治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer Inc.
• Johnson & Johnson
• Abbott Laboratories
• Bayer AG
• Sanofi SA
• GlaxoSmithKline plc
• Novartis AG
• Merck & Co., Inc.
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• AstraZeneca PLC
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Sun Pharmaceutical Industries Limited
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited
• Hikma Pharmaceuticals PLC
• Alkem Laboratories Ltd.
• Torrent Pharmaceuticals Ltd.
• Zydus Lifesciences Limited

結論與建議

Global Pleurodynia Treatment Market size was valued at USD 186.3 Million in 2024 and is poised to grow from USD 197.29 Million in 2025 to USD 312.09 Million by 2033, growing at a CAGR of 5.9% during the forecast period (2026-2033).

The global pleurodynia treatment market is driven by the need for effective therapies that alleviate pain caused by coxsackievirus B infection. The rapid onset of symptoms and frequent misdiagnosis contribute to significant productivity loss among adults, prompting heightened clinical awareness and increased prescription volumes. This has led to the introduction of innovative analgesic and antiviral treatments. Additionally, expanding outpatient pharmaceutical distribution networks enhance accessibility, while telemedicine integration offers patients quick prescriptions for antiviral-analgesic combinations, thus minimizing hospital visits. Furthermore, AI-driven drug discovery is revolutionizing the sector by expediting the identification of antiviral candidates and lowering R&D costs, allowing both small and large companies to focus on niche therapies. This dynamic landscape encourages further investment and growth opportunities within the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pleurodynia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pleurodynia Treatment Market Segments Analysis

Global pleurodynia treatment market is segmented by treatment type, route of administration, end user, distribution channel, patient group and region. Based on treatment type, the market is segmented into Analgesics, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Antiviral Therapy and Supportive Care. Based on route of administration, the market is segmented into Oral, Injectable and Topical. Based on end user, the market is segmented into Hospitals, Clinics and Homecare. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on patient group, the market is segmented into Pediatric and Adult. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pleurodynia Treatment Market

The rising prevalence of pleurodynia in various regions around the globe enhances awareness among healthcare professionals, leading to increased assessment of patients who exhibit symptoms such as chest and abdominal pain. This heightened clinical vigilance results in a higher rate of prescriptions for existing therapies and spurs interest in innovative treatment alternatives. As healthcare providers diagnose more confirmed cases, they become inclined to implement standardized management protocols, which broadens the overall patient demographic suitable for pharmacological treatments. This trajectory supports ongoing growth and development within the global pleurodynia treatment market, reflecting an expanding opportunity for therapeutic options worldwide.

Restraints in the Global Pleurodynia Treatment Market

The lack of detailed treatment protocols specific to pleurodynia creates uncertainty for clinicians regarding the best therapeutic strategies and appropriate dosing, often leading them to rely on personal experience instead of evidence-based guidelines. This ambiguity may contribute to delays in prescribing approved medications or an inclination toward supportive care options, ultimately reducing the demand for specialized treatments. Furthermore, healthcare systems may hesitate to invest in therapies that do not have strong guideline backing, which restricts market penetration and hampers overall growth, even in the face of increasing disease prevalence in various areas and restricted reimbursement options.

Market Trends of the Global Pleurodynia Treatment Market

The Global Pleurodynia Treatment market is witnessing a significant shift towards personalized medicine, as emerging immunotherapeutic agents are customized to align with specific viral strains and individual immune responses. Advances in genomic sequencing and biomarker identification are paving the way for innovative approaches, including vaccine-like therapies and monoclonal antibodies tailored to each patient's unique profile. This trend not only enhances symptom management and minimizes recurrence rates but also attracts increased investment from pharmaceutical companies keen on integrating patient-specific data into treatment paradigms. Collaborative networks among academia, clinical practices, and industry are essential for developing effective protocols that comply with regulatory standards, driving further market growth.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Pleurodynia Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Analgesics
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Antiviral Therapy
• Supportive Care

Global Pleurodynia Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Topical

Global Pleurodynia Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Homecare

Global Pleurodynia Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Pleurodynia Treatment Market Size by Patient Group & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult

Global Pleurodynia Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Route of Administration, End User, Distribution Channel, Patient Group)
  • US
  • Canada
• Europe (Treatment Type, Route of Administration, End User, Distribution Channel, Patient Group)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Route of Administration, End User, Distribution Channel, Patient Group)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Route of Administration, End User, Distribution Channel, Patient Group)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Route of Administration, End User, Distribution Channel, Patient Group)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkem Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations